Genetics Institute v. Novartis Vaccines - Patent Law Blog (Patently-O)

The Science: In the 1980's, scientists raced to develop a truncated version of Factor VIII, an essential blood-clotting protein. Two companies, Genetics and Novartis, successfully developed and patented truncated versions of this 2,332 amino acid protein. Genetics' patent, with a 1985 priority date, included claims directed at a version of the protein that removed between 581 and 949 amino acids in the region between amino acid...